Momelotinib Offsets Transfusion-Related Burden and Costs in Myelofibrosis Treatment

A recent study published in Cancers evaluated the economic and time burdens associated with red blood cell transfusions in patients with myelofibrosis (MF) undergoing treatment with momelotinib compared to ruxolitinib or best available therapy (BAT). The analysis utilized 24-week transfusion data from the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials, focusing on JAK inhibitor-naive and JAK inhibitor-experienced patients. Cost estimates were derived from the US IBM MarketScan Commercial database.

In JAK inhibitor-naive patients, momelotinib demonstrated significant cost and time savings compared to ruxolitinib across all patient subgroups, including those who were transfusion-dependent and transfusion-independent/requiring. Similarly, in JAK inhibitor-experienced patients, momelotinib showed economic and time benefits over BAT, particularly in transfusion-dependent patients. The study concluded that "momelotinib may provide medical and transfusion-related cost and time burden offsets for both JAK inhibitor-naive and -experienced patients with MF."

These findings suggest that incorporating momelotinib into treatment plans for patients with MF could reduce the reliance on red blood cell transfusions, thereby decreasing associated health care costs and patient time commitments. Clinicians may consider these potential benefits when selecting therapeutic strategies for managing MF-related anemia.

Reference

Masarova L, Liu T, Fillbrunn M, et al. Transfusion-related cost and time burden offsets in patients with myelofibrosis treated with momelotinib in the SIMPLIFY-1 and SIMPLIFY-2 trials. Cancers. 2024;16(23):4067. doi:10.3390/cancers16234067.